Valuation: Mylan Inc

Market Cap 1.85TCr 1.62TCr 1.49TCr 1.39TCr 2.63TCr 1,74900Cr 2.67TCr 18TCr 6.96TCr 86TCr 6.95TCr 6.79TCr 3,00600Cr P/E 2026 *
58.1x
P/E 2027 * 25.2x
Enterprise Value 3.07TCr 2.69TCr 2.48TCr 2.31TCr 4.36TCr 2,90100Cr 4.43TCr 30TCr 12TCr 1,43100Cr 12TCr 11TCr 4,98700Cr EV / Sales 2026 *
2.08x
EV / Sales 2027 * 1.96x
Free-Float
92.12%
Yield 2026 *
3.2%
Yield 2027 * 3.29%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%+6.28%+53.04%+157.34% 1,07000Cr
-0.66%+5.15%+62.53%+55.14% 61TCr
-1.07%+6.39%+31.53%+85.09% 44TCr
-3.05%+4.18%+31.11%+23.88% 33TCr
-1.64%+0.17%+33.96%+34.32% 29TCr
-0.46%+0.32%+27.42%+40.89% 29TCr
+2.99%+4.00%-26.09%-40.14% 21TCr
-1.15%+2.93%+24.50%+60.75% 20TCr
-0.16%+1.03%+13.17%+64.83% 16TCr
Average -0.66%+5.04%+27.91%+53.57% 39.96TCr
Weighted average by Cap. -0.88%+6.67%+38.43%+78.65%

Financials

2026 *2027 *
Net sales 1.48TCr 1.29TCr 1.19TCr 1.11TCr 2.1TCr 1,39700Cr 2.14TCr 14TCr 5.56TCr 69TCr 5.55TCr 5.43TCr 2,40100Cr 1.5TCr 1.32TCr 1.22TCr 1.13TCr 2.14TCr 1,42200Cr 2.17TCr 15TCr 5.66TCr 70TCr 5.65TCr 5.52TCr 2,44400Cr
Net income 1.3Cr 1.14Cr 1.05Cr 97.96L 1.85Cr 122.89Cr 1.88Cr 13Cr 4.89Cr 61Cr 4.88Cr 4.77Cr 211.27Cr 50Cr 44Cr 40Cr 37Cr 71Cr 4.7TCr 72Cr 482.21Cr 187.21Cr 2.32TCr 186.92Cr 182.75Cr 8.09TCr
Net Debt 1.22TCr 1.07TCr 984.69Cr 918.52Cr 1.73TCr 1,15200Cr 1.76TCr 12TCr 4.59TCr 57TCr 4.58TCr 4.48TCr 1,98100Cr 1.1TCr 965.5Cr 891.27Cr 831.37Cr 1.57TCr 1,04300Cr 1.59TCr 11TCr 4.15TCr 51TCr 4.14TCr 4.05TCr 1,79300Cr
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-